An interactive tool from Biosimilars Forum, an industry group, uses data from Pacific Research Institute to calculate potential biosimilar savings based on 75% market share.
How much could New Jersey save with biosimilars annually? The answer is $294.2 million, if biosimilars achieve a 75% market share, according to an interactive tool developed by Biosimilars Forum using Pacific Research Institute data.
The tool can provide similar savings information for every other state in the union, including Hawaii, California, Arkansas, and Florida ($45.1 million, $1.0 billion, $148.8 million, and $960.6 million, respectively).
In total, the tool predicts annual savings of $14.08 billion annually from biosimilars. The tool bases those savings on biosimilars achieving a 75% market share in each state.
The reality is that actual biosimilar market share is well below that level for many therapeutic and supportive care categories. Only in the filgrastim category is biosimilar share above 75%—the actual share is 78%—according to Amgen’s 2021 Biosimilar Trends Report.
Trastuzumab biosimilars have achieved a 70% share in the United States, relative to the reference product (Herceptin), and bevacizumab biosimilars are close behind with 69%, relative to the originator (Avastin), according to Amgen.
Infliximab, epoetin alfa, and pegfilgrastim biosimilars all have market shares under 40% relative to their originator products.
These hurdles are acknowledged in the Biosimilars Forum interactive tool report. “Misaligned incentives have made these medicines difficult for patients to access and physicians to prescribe. The current provider reimbursement system does not financially encourage the prescribing of lower-cost biosimilars," the report notes.
Sandoz in a recent report estimated US total biosimilar savings of $2.2 billion in 2019. The company was the first to bring a biosimilar to market (Zarxio, filgrastim; 2015). The Sandoz report was in agreement with the Biosimilars Forum in estimating potential 5-year savings of $100 billion from biosimilars.
The Biosimilars Forum called upon Congress and President Joe Biden to “enact commonsense policy changes” that would spur greater use of biosimilars and “unlock these savings.”
Eye on Pharma: BI Cyltezo Partnership; Europe Ustekinumab Launch; Mexico Biosimilar Approval
July 24th 2024Boehringer Ingelheim (BI) partners with GoodRx to offer its unbranded adalimumab biosimilar to patients at an exclusive low price; a new ustekinumab biosimilar launches in Europe; and Mexican officials approve a bevacizumab biosimilar.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Biosimilars Oncology Roundup for June 2024—Podcast Edition
July 7th 2024On this episode of Not So Different, we review biosimilar news coming out of June, with clinical trial results from conferences and a study showcasing how to overcome economic and noneconomic barriers to oncology biosimilars.
Hesitancy in MENA Nations to Adopt WHO Biosimilar Guidelines Hinders Market Development
July 17th 2024The World Health Organization’s (WHO) new guidelines for biosimilar approvals aim to save time and money for manufacturers in the Middle East and North Africa (MENA), but hesitancy among nations to adopt the guidelines is stifling market development of biosimilars.